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Summary
Streptomyces diastaticus var. 108, a newly isolated
strain, was recently characterized as a producer of
two polyene macrolide antibiotics (rimocidin and CE-
108), and the biosynthetic gene cluster was partially
characterized. When the producer strain was geneti-
cally modified by transformation with some engineered
SCP2*-derived vectors carrying the ermE gene, two pre-
viously uncharacterized macrolides were detected in
the fermentation broth of the recombinant strain and
chemically characterized as the amides of the paren-
tal polyene carboxylic acids. The biological activity
and some in vitro toxicity assays showed that this
chemical modification resulted in pharmaceuticals
with improved biological properties compared with
the parental products.
Introduction
The polyenes are a group of macrolide polyketides that
are interesting because of their antifungal activity.
These compounds contain a macrolactone ring with
several conjugated double bonds, forming chromo-
phores with characteristic ultraviolet/visible light spectra;
these features are responsible for the physical and
chemical properties of the compounds (strong light ab-
sorption, photolability, and poor solubility in water) [1,
2]. Despite the importance of some polyenes, such as
amphotericin B (1; Figure 1), as antifungal drugs, their
precise mechanism of action is still not well under-
stood; nevertheless, antifungal activity seems to be due
to interactions between polyene molecules and sterol-
containing membranes. This interaction results in an
ion channel and the membranes become permeable,
causing destruction of electrochemical gradients and
consequent cell death [3]. These compounds show sig-
nificantly higher affinity for ergosterol-containing mem-
branes (the main sterol present in fungal membranes)
than for cholesterol-containing membranes (mamma-
lian cells) [4]. However, the interaction between poly-
enes and cholesterol-containing membranes is not
negligible and causes some side effects, which, along
with low solubility, makes the compounds not fully sat-
isfactory for treating systemic fungal infections. De-*Correspondence: fmalpart@cnb.uam.esspite its undesirable properties, amphotericin B (1) has
been used for more than 40 years and there is a con-
sensus that there are no better alternatives available to
fight emerging fungal diseases.
For this reason, the finding of new antifungal drugs
or improving the pharmacological properties of the old
ones has become an exciting challenge. With this aim,
and using rational molecular modeling approaches,
many semisynthetic derivatives of amphotericin B (1)
have been generated and tested as efficient antifungal
drugs. Two main targets were considered for structural
modifications, among others: the side-chain carboxyl
group and the amino group of the sugar moiety [5–11].
Whereas some of these semisynthetic derivatives still
showed the same toxicity, others had improved phar-
macological features compared with the parental am-
photericin molecule: higher antifungal activity, water
solubility, specificity for ergosterol-containing mem-
branes, and less hemolytic activity, suggesting more
specificity for ergosterol-containing membranes. Al-
though the higher antifungal activity confers some ad-
vantage to those compounds, surprisingly these struc-
tural modifications are not widely represented within
the natural polyenes isolated from microorganisms.
One exception is the polyene AB-400 (2b; Figure 1), an
amide of pimaricin (2a; Figure 1), recently reported as
a natural product isolated from Streptomyces costae
[12] along with other tetraene derivatives. AB-400 (2b)
was also detected in a different strain isolated in our
laboratory in a screening program for producers of anti-
fungal compounds (Streptomyces sp. RGU5.3, unpub-
lished data).
We have recently characterized a chromosomal re-
gion of Streptomyces diastaticus var. 108 involved in
the biosynthesis of two related polyenes: rimocidin and
CE-108 (3a and 4a, respectively; Figure 1) [13]. Both
compounds are derived from the same biosynthetic
pathway in which the rimA gene, coding for the loading
module PKS, plays a pivotal role in the balance of the
two polyenes through its choice of the starter unit (ace-
tyl-CoA or butyryl-CoA). This versatility in the recogni-
tion of the building blocks for rimocidin or CE-108 bio-
synthesis makes this biosynthetic cluster a promising
system in the effort to generate new bioactive mole-
cules.
Results
Generation of a Recombinant rimA Gene
The rimA gene [13] was engineered with the aim of gen-
erating new recombinant molecules using the rimocidin
and CE-108 gene cluster. Because rimA is coded within
a polycistronic mRNA, the structural gene was cloned
under the control of the xysA promoter (xysAp) of the
xylanase gene of Streptomyces halstedii JM8 [14]. The
xysAp was excised from pHis1 as a 547 bp BglII/SmaI
fragment also carrying the terminator of the methyleno-
mycin resistance gene (T1) [15] upstream of xysAp. Af-
ter several cloning steps described in Table 1, a DNA
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536Figure 1. Chemical Structures of the Rele-
vant Tetraenes Cited within the Text
The structures were: amphotericin B (1);
pimaricin (2a); AB-400 (2b); rimocidin (3a);
rimocidin B (3b); CE-108 (4a); and CE-
108B (4b).site (inside the thiostrepton resistance marker) of a low-[13] was fused with xysAp. In order to allow selection
Table 1. Bacterial Strains and Vectors Used in this Study
Strain or Plasmid Properties Reference
S. diastaticus var. 108 WT, CE-108 and rimocidin producer [17]
S. diastaticus var. 108/922 WT transformed with pIJ922 plasmid (WT, control) This work
S. diastaticus var. 108/PM1-500 WT derivative with rimA-disrupted by integration of PM1-500; CE- [13]
108 and rimocidin non-producer
S. diastaticus var. 108/743B WT derivative transformed with pSM73B; CE-108, rimocidin, CE- This work
108B and rimocidin B producer
S. diataticus var. 108::PM1-500/743B WT derivative with rimA-disrupted by integration of PM1-500 and This work
transformed with pSM743B; CE-108, rimocidin, CE-108B and
rimocidin B producer
S. diastaticus var. 108/784 WT derivative transformed with pSM784; CE-108, rimocidin, CE- This work
108B and rimocidin B producer
Streptomyces sp. RGU5.3 WT; pimaricin and AB-400 producer This work
E. coli JM101 General cloning host [35]
S. lividans TK21 General cloning host [33]
Penicillium chrysogenum ATCC10003 Antifungal activity assays ATCC
Candida albicans ATCC10231 Antifungal activity assays ATCC
C. krusei ATCC14243 Antifungal activity assays ATCC
Aspergillus niger ATCC1004 Antifungal activity assays ATCC
Cryptococcus neoformans ATCC10226 Antifungal activity assays ATCC
pIJ922 Vector based on the SCP2* replicon, tsr, 24 kb [36]
pIJ941 Vector based on the SCP2* replicon, tsr, hyg, 25 kb [36]
pNAe-1 Replicative vector in E. coli, ermE, KmR. N. Allende, personal
communication
pHis1 Replicative vector in E. coli carrying xylanase xysA promoter (xysAp), [14]
ApR, 3.7 kb
pSM736 1.2 kb SacI-DraIII and 4.9 kb DraIII-BglII fragments containing rimA This work
cloned simultaneously into the SacI/BamHI sites of pIJ2925
pSM738 6.1 kb BglII-PstI fragment of pSM736 (rimA gene) and 1.7 kb PstI- This work
SphI fragment of pNAe-1 (ermE gene resistance) cloned
simultaneously into the SmaI/SphI sites of pHis1
pSM743B 8.4 kb BglII fragment of pSM738 (containing xysAp, rimA, and ermE) This work
cloned into the EcoRV site of pIJ922 (see Figure 2).
pGAe-1 Replicative vector in E. coli, ermE, ApR. A. González, personal
communication
pSM784 1.8 kb SspI-EcoRV fragment of pGAe-1 (ermE gene resistance) This work
cloned into the EcoRV site of pIJ941 (see Figure 2)
Ap, ampicillin; ermE, erythromycin resistance gene; hyg, hygromycin resistance gene; Km, kanamycin; tsr, thiostrepton resistance gene; WT,
wild-type.fragment from the rim cluster containing rimA and the o
(3# end of the rimI gene (9,336–15,445 bp from the se-
quence deposited under accession number AY442225) tf recombinant strains, the ermE gene from pNAe-1
see Table 1) was also cloned in the same fragment and
he resultant construction was cloned into the EcoRV
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537copy number Streptomyces vector (pIJ922). The re-
combinant plasmid (pSM743B) (Figure 2A) conferred
erythromycin but not thiostrepton resistance.
In order to test the functionality of the recombinant
rimA, pSM743B was introduced by transformation into
S. diastaticus var. 108 (wild-type), giving rise to S. dia-
staticus var. 108/743B (a wild-type strain carrying extra
copies of the recombinant rimA gene). The recombi-
nant plasmid was transferred from this strain to the
rimA-disrupted mutant (S. diastaticus var. 108/PM1-
500) [13] by intraspecific conjugation, producing S. dia-
staticus var. 108::PM1-500/743B. Plasmid extraction
and Southern hybridization confirmed that the rimA-
disrupted mutant carries, as expected, the engineered
copy of the intact rimA; therefore rimA expression is
under the control of the heterologous promoter.
The fermentation broths from the two recombinant
strains (wild-type and disrupted mutant, both carrying
the engineered rimA) were tested for rimocidin and CE-
108 production by HPLC analysis; the chromatograms
showed that the production of both tetraenes was re-
stored in the disrupted mutant. Polyene production was
significantly lower in the complemented rimA-disrupted
mutant than that of the engineered wild-type strain and
wild-type control (carrying the pIJ922 vector) (see Table
1); this lower production was not significantly altered
when either glucose or xylane was added to the me-
dium. The explanation for this finding probably involves
the efficiency of xysAp in driving expression of the rimA
gene, suggesting that expression of rimA would be a
limiting step in the production of the polyenes. Surpris-
ingly, in the rimA-disrupted mutant transformed with
the engineered rimA gene, what we believe to be new
polyenes were observed in addition to the expected
complementation. A similar profile was also seen in theFigure 2. Physical Maps of Recombinant
Plasmids and the Chromatographic Profile of
the Fermentation Broth from Genetically
Modified Strains
(A) Engineered rimA in pIJ922 (pSM743B).
(B) Engineered ermE in pIJ941 (pSM784).
(C) HPLC analysis of the fermentation broth
of S. diastaticus var. 108/743B recombinant
strain (see text).
The numbers represent: CE-108B (1); CE-108
(2); rimocidin B (3); and rimocidin (4). ermE,
erythromycin resistance gene; hyg, hygro-
mycin resistance gene; rimA, type I PKS in-
volved in CE-108 and rimocidin biosynthetic
pathway; T1, terminator of methylenomycin
resistance gene; tsr, thiostrepton resistance
gene; rimI*, rimI truncated at its N terminus;
xysAp, xysA promoter.recombinant S. diastaticus var. 108 carrying the engi-
neered rimA; these apparently new compounds showed
characteristic visible/UV tetraene spectra similar to ri-
mocidin and CE-108 (see Figure 2C). Due to their prox-
imity in retention time to the native compounds within
the chromatogram, these polyenes were named rimoci-
din B and CE-108B, respectively (3b and 4b; Figure 1).
In order to exclude the possibility that production of
these compounds was due to a possible degradation
of CE-108 and/or rimocidin, the timing profile for pro-
duction of both compounds was compared with that of
the original compounds. The results clearly showed
that all the compounds followed a similar production
profile (data not shown), suggesting that the formation
of the compounds was not due to degradation of the
natural compounds. However, the tetraenes production
in S. diastaticus var. 108/743B and S. diastaticus var.
108::PM1-500/743B strains was delayed compared
with the wild-type control, S. diastaticus var. 108/922.
Differences in temporal expression of the recombinant
rimA compared with the wild-type could explain the de-
lay in polyene production. This different temporal ex-
pression could alter the availability of some metabolites
needed for this apparently new biosynthetic process.
A construction was developed in order to investigate
the possibility that this phenotype could be due to the
erythromycin used for selection in the culture medium.
A blunt-ended fragment carrying the ermE gene (see
Table 1) was inserted into the EcoRV site of pIJ941 (a
vector similar to pIJ922, which was used for generating
the recombinant rimA gene); pSM784, carrying ermE in
the same orientation as in pSM743B, was selected (Fig-
ure 2B). This plasmid was introduced by transformation
into the wild-type strain. Unexpectedly, when HPLC
analysis was performed with this strain, the tetraenes
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538(CE-108B and rimocidin B) were also detected. These [
oresults clearly indicate that the ermE gene in the
SCP2*-derived vector plays a pivotal role in generating δ
ithe polyenes. It is noteworthy that neither erythromycin
resistance (cloned for other purposes [unpublished v
ddata] in different vectors, such as pHJL401 [16]) nor
SCP2*-derived vectors, independently, are enough for w
tproduction of the new structures. Further experiments
are in progress in order to clarify the mechanism of the t
bpolyenes’ formation.
s
1Characterization of the Polyenes
wHPLC-MS Analysis
aHPLC-MS analysis of the fermentation broth from
S. diastaticus var. 108/743B and S. diastaticus var.
108::PM1-500/743B were carried out; the deduced B
Amasses for the two tetraenes were 738 and 766 Da for
the lower and higher retention times, respectively. In T
tboth cases the mass of the polyenes is one unit lower
than that of the polyenes with the closest retention C
atime, CE-108 (739 Da) and rimocidin (767 Da). Both the
mass differences and the chromatographic mobility t
asupported the idea that the two polyenes were derived
from the natural macrolides. t
tChemical Structure Elucidation
The two tetraenes were preliminarily characterized in t
torder to develop a procedure for their purification with
the aim of structure elucidation. Both compounds in- t
cteract not only with reverse-phase silica gel, such as C8
and C18, but also with an ion exchange resin, like SP- c
aSepharose, suggesting that these compounds have an
accessible positive charge. This preliminary character- m
Tization allowed us to design a straightforward purifica-
tion procedure from the fermentation broth of S. diastat- F
cicus var. 108/pSM743B (see Experimental Procedures).
Compound 4b was obtained as a yellow powder with 1
ta typical tetraene UV spectrum (λmax = 317,302,289
nm), similar to that of 4a [17]. The proton NMR c
mspectrum with three signals in the sp2 range at δ 6.25
(dd, 14.9, 10.9 Hz), a multiplet at d 6.00-6.15 and a w
Hdoublet of doublet at δ 5.87 (15.2, 8.4 Hz) was similar
to that of 4a as well. Two exchangeable protons ap- (
apeared at δ 7.30 and 6.83 as broad singlets. In the ali-
phatic range of δ 1.40–2.50, the spectrum displayed a a
icomplex multiplet pattern, and signals of three methyl
triplet and doublets, respectively, appeared at δ 1.17, 1
t1.15, and 0.83. Electrospray ionization mass spectrom-
etry (ESI MS) afforded pseudomolecular ions atm/z 739 t
s([M+H]+) and 761 ([M+Na]+), which delivered the molec-
ular formula C37H58N2O13 by high resolution (found (
w739.40110, calculated 739.40118 for [M+H]+). The 13C-
NMR spectrum indicated 37 carbon signals as in 4a o
cand as demanded by the molecular formula. The 13C
data of 4a and 4b were closely related (Table 2) and t
Cpermitted the conclusion that 4a and 4b possess the
same carbon skeleton, including the amino sugar. Ac- (
acording to these data, the second nitrogen must be at-
tributed to an amide function, which identifies CE-108B n
a(4b) as the amide of 4a.
The yellow powdery 3b was readily soluble in DMSO. p
(ESI MS fixed the molecular weight of 3b as 766 Da,
and NMR delivered the molecular formula C39H62N2O13
a(found 767.43254 Da, calculated 767.43301 Da forM+H]+). The proton NMR spectrum was similar to that
f 4b and displayed two H/D exchangeable protons at
7.30 and 6.83, two doublet of doublets and a multiplet
n the range of δ 6.40–5.80. The aliphatic region was
ery complex due to less resolution, but a triplet and a
oublet at δ 1.83 and 1.16, attributed to methyl signals,
ere easily identified. The 13C NMR spectrum indicated
he presence of 39 carbon signals. Comparison with
hat of CE-108B (4b) revealed the presence of three car-
onyl signals at 208.8, 174.1, and 172.1, in addition to
ignals of eight sp2 carbon atoms in the range of 136.7–
28.3 and of two acetal groups. The close similarity
ith 4b identified this compound finally as rimocidin
mide (3b).
iological Activity of the Compounds
ntifungal Activity Assays
he antifungal activity of the tetraene amides was
ested against several fungi: Penicillium chrysogenum,
andida albicans, Aspergillus niger, Candida krusei,
nd Cryptococcus neoformans. Increasing concentra-
ions of different tetraenes dissolved in methanol were
pplied to paper discs (9 mm diameter), dried, and
ransferred to the bioassay plates. The activity of these
etraene amides was compared with that of the paren-
al molecules (CE-108 [4a] and rimocidin [3a]), showing
hat the biological activity of the amides on all fungi
ested was substantially higher compared with their
orresponding parental tetraenes (Figure 3). In both
ases, substitution of the free carboxylic group for the
mide group increased antifungal activity approxi-
ately four times.
oxicity Assays
rom the previous experiments it was clear that modifi-
ation of the polyenes produced by S. diastaticus var.
08 gave rise to compounds with higher antifungal ac-
ivity. In order to test if toxicity was also enhanced, we
arried out some preliminary determinations of the he-
olytic activity of the molecules. Human erythrocytes
ere used as a cellular model for this study [7, 18].
emolytic activity of the compounds was evaluated
see Experimental Procedures) versus rimocidin (3a)
nd CE-108 (4a); amphotericin B (1) and nystatin A were
lso included. As shown in Table 3, the hemolytic activ-
ty of the tetraene amides (rimocidin B [3b] and CE-
08B [4b]) was not significantly different from that of
heir corresponding parental tetraenes, whereas its an-
ifungal activity was clearly higher. Noteworthy are the
trong differences in toxicity observed between CE-108
4a)/CE-108B (4b) and rimocidin (3a)/rimocidin B (3b);
hereas 50% of hemolysis is reached with 40–60 nmol
f these two last polyenes, a 6- to 7-fold greater con-
entration of CE-108 and its amide are needed. Thus,
he pharmacological properties of the amide polyene
E-108B (4b) are clearly enhanced: although CE-108
4a) shows low antifungal activity, its structurally related
mide 4b has an increased antifungal activity level
early as high as that of rimocidin (3a), but its hemolytic
ctivity is 6- to 7-fold lower. These assays were also
erformed with horse blood, resulting in similar findings
data not shown).
Identical results were obtained using pimaricin (2a)
nd its amide AB-400 (2b). Both were purified from our
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539Table 2. 13C-NMR Chemical Shifts of Rimocidin B (3b), CE-108 (4a), and CE-108B (4b) in DMSO-d6
C No. 4a 4b 3b C No. 4a 4b 3b
1 173.4 173.3 172.1 17 78.2 78.2 74.2
2 56.3 57.4 56.0 18 136.0 137.4 136.7
1## 22.4 23.4 22.6 19 133.6 134.6 133.1
2## 10.9 12.0 11.7 20 129.3 130.0 128.3
3 68.5 69.7 68.3a 21 133.4 133.6 132.8
4 48.8 49.6 48.3 22 132.3 134.4 131.3
5 210.6 211.5 208.8 23 132.3 133.2 131.5
6 44.3 45.2 43.5 24 132.6 134.4 131.8
7 19.6 20.6 21.8 25 131.1 132.2 130.8
8 37.6 38.6 37.6 26 40.0 41.0 37.4
9 68.4 69.5 67.5 27 70.8 71.8 72.4
10 46.5 47.1 44.7 28 20.0 21.0 37.1a
11 97.8 98.8 96.9 29 — — 17.7
12 44.1 45.1 45.3a 30 — — 13.7
13 69.9 69.9 69.6 1# 98.2 99.0 97.1
14 60.5 58.6 56.7 2# 68.0 69.4 64.7
14-COOH 179.3 — — 3# 56.1 57.4 56.5
14-CONH2 — 177.7 174.1 4# 69.5 71.2 72.9
15 66.6 66.8 65.3 5# 73.5 74.6 73.0
16 38.7 39.0 36.4 6# 16.7 17.8 17.9
aExpected value according to Sowinski et al. [37]; in our measurement, the signal was missing.creases in the incidence of nosocomial fungal infec-results, summarized in Figure 4C, are in good agree-
Figure 3. Antifungal Activity of the Four Tetraenes Produced by S. diastaticus var. 108/743B
(A) Rimocidin (3a).
(B) Rimocidin B (3b).
(C) CE-108 (4a).
(D) CE-108B (4b).
The applied quantities for each polyene are expressed in nanomoles. The target organisms were P. chrysogenum, C. krusei, A. niger,
C. albicans, and C. neoformans (see Table 1).isolated strain RGU5.3 as indicated in the Experimental
Procedures. The strain was cultivated in a medium sup-
plemented with either glucose or sodium acetate.
Using a fermentation broth containing glucose as a car-
bon source, pimaricin (2a) comprised nearly 70% of the
produced polyenes; in an acetate-containing medium,
the production profile was reversed, with AB-400 (2b)
being the compound that was mainly produced (Figure
4). This effect was not observed in the engineered
S. diastaticus var. 108 strain producing the polyene am-
ides. AB-400 (2b) was purified from this medium and
tested for both antifungal and hemolytic activities. Thement with the previous finding: whereas pimaricin (2a)
displayed no detectable antifungal activity at the con-
centration tested, the same amount of AB-400 (2b) was
active. However, the hemolytic activity assays carried
out with AB-400 (2b) and commercial pimaricin (2a)
showed no significant differences between the two
polyenes. This is an instance in which the polyene car-
boxamide has a clear advantage over the free acid.
Discussion
In recent decades we have witnessed dangerous in-
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540Table 3. Comparative Hemolytic Activity of Several Polyenes (See Experimental Procedures)
Hemolytic Activity (% of Total Hemolysis)
Test Value
(nmol) Amphotericin B (1) Nystatin A Rimocidin (3a) Rimocidin B (3b) CE-108 (4a) CE-108B (4b)
1 1.97
2 4.47
3 82.26
4 100.00
20 2.20 10.00 10.00
40 49.53 21.18 33.51
60 76.80 65.02 84.80
80 92.79 95.59 94.80
100 100.00 100.00 100.00
120 11.72 12.01
160 14.48 15.86
200 16.60 23.29
240 26.89 30.22
280 32.47 34.86
320 44.25 40.39
360 63.56 61.34
400 82.12 88.26
440 100.00 100.00ceuticals currently available for treating systemic infec- been developed by targeting specific components of
Figure 4. Biological Activities of Pimaricin and AB-400 Polyenes Extracted from Streptomyces sp. RGU5.3
(A) HPLC analysis of the fermentation broths from Streptomyces sp. RGU5.3 in media with acetate.
(B) HPLC analysis of the fermentation broths from Streptomyces sp. RGU5.3 in media with glucose as carbon source.
(C) Antifungal activity of pimaricin (2a) and AB-400 (2b) against P. chrysogenum. The polyene samples applied were: commercial pimaricin
(1) (Calbiochem 527962), total extract from Streptomyces sp. RGU5.3 fermentation broth grown in glucose medium (2), purified AB-400 from
Streptomyces sp. RGU5.3 (3) and purified pimaricin from Streptomyces sp. RGU5.3 (4); a total of 200 ng were added at each test.
(D) Hemolytic activity for pimaricin (Calbiochem 527962, 98.8% purity) and AB-400 (HPLC-purified as indicated in Experimental Procedures).
The values of each polyene are expressed in nanomols (left column) and the corresponding hemolytic activities are given as percentage of
total hemolysis (see Experimental Procedures).tions. Several factors have contributed to these increases, t
asuch as with the effects of AIDS, chemotherapy, and
treatment with immunosuppressant agents. Despite the f
yneed for new antifungal drugs, the number of pharma-ions is dangerously low. Most of them, such as azoles
nd amphotericin B (1), target the structural integrity of
ungal membranes [3, 19]; although, in the last few
ears, new antifungal drugs (e.g., echinocandins) have
Tetraene Amides Produced by Streptomyces Strains
541the cell wall [20]. Despite the toxic side effect of am-
photericin B (1), this old drug remains the preferred an-
tifungal agent for treating most systemic infections;
some of the undesirable effects can be minimized by
delivering the drug in a liposomal formulation [21, 22].
This successful reduction in the toxicity level of ampho-
tericin B (1) with the new formulations has increased
the clinical interest in this old drug; thus, amphotericin
B (1) is undoubtedly a good model to use in attempts
to generate new and improved pharmaceuticals.
These attempts have attracted large efforts in aca-
demic laboratories as well as within the pharmaceutical
industry, resulting in the generation of several new de-
rivatives of amphotericin B (1). Most attention has fo-
cused on deciphering the physicochemical interactions
between the drug or its chemical derivatives and its
target membranes, as well as the pharmacokinetic
properties of its semisynthetic derivatives [4–8, 11, 22–
26]. Although not conclusive, all the experimental data,
as well as those based on molecular dynamic simula-
tion [4], have allowed some preliminary conclusions
about the relationships between chemical structure and
biological activity of these derivatives. All these tech-
niques elicited novel approaches for designing a new
generation of drugs following a more rational design of
their chemical structure [27]. As a result of these efforts,
there is a clear conclusion: two structural changes
within the amphotericin B molecule seem to be impor-
tant for improving its pharmacological properties. These
changes are based on modifications of the carboxyl
group and the sugar moiety [7, 11, 26, 28]. All the poly-
ene compounds referred to in the literature as improved
pharmaceuticals are semisynthetic derivatives and are
generated by organic synthesis rather than by biotrans-
formations. In this work, we describe the biosynthesis
of two polyenes with changes in the carboxylic group
generated by genetic manipulation.
S. diastaticus var. 108, a producer of two natural tet-
raenes [17], has the ability to naturally produce, as ma-
jor compounds, the corresponding amides if it is appro-
priately engineered by genetic manipulation. As with
other semisynthetic polyene derivatives, conversion of
the free carboxylic group into the amide group results
in a clear improvement of some pharmacological prop-
erties (substantial increase of antifungal but not hemo-
lytic activities), thus giving an apparent advantage over
native tetraenes. This chemical modification in both de-
rivatives caused an increase in the selective toxicity to-
ward ergosterol-containing membranes. A similar result
was obtained with pimaricin (2a) and its derivative, AB-
400 (2b), which reinforces the idea that the substitution
of the carboxylic group for an amide group will also
improve the selective toxicity of other polyenes.
What are the origins of the new amidated tetraenes?
Analysis of polyene production in S. diastaticus var. 108
wild-type by HPLC revealed that some minority tet-
raene compounds are also produced along with the
major compounds. Using HPLC analysis coupled with
a mass detector, we could detect tetraenes with a mass
and retention time identical to the amidated derivatives.
This allowed us to conclude that the identified polyene
amides are likely being produced by the wild-type
strain, although at an extremely low level. Genetic ma-nipulation of the producer strain elicits overproduction
by a mechanism that is not yet fully understood. One
important lesson is noteworthy: paying attention to mi-
nor active metabolites in the fermentation broth of pro-
ducer strains might be a good alternative for isolating
new and interesting pharmaceuticals.
Although the precise mechanism of the biosynthesis
of these metabolites is still unknown, at least two plau-
sible mechanisms can be postulated. In one, the am-
ides would be the result of an amidotransferase activity,
as a tailoring function (post-PKS modification), which,
under natural conditions, is poorly expressed. In the
other, malonamyl-CoA would be incorporated by mod-
ule 7 of the corresponding PKS instead of methylmalo-
nyl-CoA, as proposed in the biosynthetic model for CE-
108 (4a) and rimocidin (3a) production [13]. In this latter
case, a type of nondecarboxylating Claysen condensa-
tion would be required for the incorporation of malon-
amide, as it happens in the biosynthetic thiolases [29].
The availability of malonamide as a condensing unit
would be crucial for good incorporation into the grow-
ing polyketide chain. It is noteworthy that the producer
strain also biosynthesizes oxytetracycline [17], the pos-
tulated starter unit of which is malonamide [30], so this
metabolite would be easily available for secondary me-
tabolite production in this strain.
Undoubtedly we are far from having complete eluci-
dation of the genetic mechanism leading to CE-108B
(4b) and rimocidin B (3b) production. So far it is clear
that both the ermE gene and either pIJ922 or pIJ941
plasmids are simultaneously required to trigger biosyn-
thesis of the new amides. It has been recently de-
scribed that subinhibitory concentrations of erythromycin
can modulate bacterial transcription [31]. Nevertheless,
the possibility that erythromycin could modulate the
expression of a possible transcriptional regulator, mak-
ing possible the amidation step in our polyene pro-
ducer, can be ruled out because the amides were also
detected in cultures with no erythromycin added. This
allows the possibility that the ermE product (a methyl-
ase) might be targeting another intermediate gene,
coded within the plasmid DNA, the final target of which
would be activation of a chromosomal gene responsi-
ble for the amidation. Insight into the mechanism of this
modification will provide an interesting tool for ap-
proaching the exciting challenge of generating new
polyene amides by biotransformation. This would un-
doubtedly be a straightforward process for production
of improved pharmaceuticals if successfully applied to
the biosynthetic pathway of commercial polyenes.
Significance
Through genetic manipulation of a polyene producer
(Streptomyces diastaticus var. 108), we could gener-
ate a strain that produces, to our knowledge, new bio-
active compounds. The polyenes are amides of the
parental tetraenes with higher selectivity for fungal
membranes. This finding opens the possibility of gen-
erating recombinant strains, producing polyene am-
ides by biotransformation, and thus new antifungal
drugs with improved pharmacological properties. The
Chemistry & Biology
542mbiosynthetic process would undoubtedly be an inter-
aesting tool that may well compete with semisynthetic
amethods described in the literature.
f
sExperimental Procedures
HBacterial Strains and Growth Conditions
TBacterial strains and plasmids are described in Table 1. S. diastat-
Gicus var. 108 and its engineered derivatives were routinely grown in
dliquid and solid SYM2 medium [32] for tetraene production analy-
fsis, and liquid TSB medium (Oxoid) for plasmid and total DNA ex-
atraction. Streptomyces lividans TK21 was used as a general cloning
ihost and grown in solid R5 medium and liquid YEME medium [33].
3Escherichia coli strains were grown in Luria-Bertani (LB) agar or in
hLB broth [34]. P. chrysogenum, C. krusei, A. niger, C. albicans, and
vC. neoformans, used for testing antifungal activity, were grown in
pMPDA medium (2% malt extract, 2% glucose, 0.1% Bacto peptone).
(
CGenetic Procedures
bE. coli strains were grown and transformed as described elsewhere
l[34]. Streptomyces strains were manipulated as previously de-
bscribed [33]. Intraspecific conjugation was carried out by growing
stogether the donor and recipient strains in solid R5 medium without
selection and then selecting for the corresponding antibiotic resist-
ances of the plasmids and genetic markers of the recipient strains.
DNA manipulations were performed as described by Maniatis et A
al. [34].
T
Assay for Tetraenes Production B
Tetraenes production was analyzed by extracting whole culture t
with methanol as previously described [13]. The extracts were fil- p
tered and applied to an HPLC with a Waters 600S Controller, p
equipped with a Waters 996 PDA; quantitative determination and s
chromatographic conditions were as previously described [17]. S
HPLC-MS Assays
RThe mass spectra were determined in an 1100MSD HPLC con-
Rnected to a quadrupole Agilent Technology Detector, using electro-
Aspray as the source and a positive ionization mode. The chromato-
Pgraphic conditions were the same as described above.
Purification of the Compounds R
S. diastaticus var. 108/743B was cultivated in either solid or liquid
SYM2 medium [17]. After 6 days, the whole solid medium was frag-
mented through a 50 ml syringe and extracted with four volumes
of methanol and 25 mM formic acid; cultures from liquid medium
were freeze-dried before similar extraction with methanol. The
aqueous suspension was stirred for 1 hr and clarified at 5000 × g
for 20 min to remove solid particles. The clear supernatant was
concentrated by rotaevaporation to 10–20 × 106 U/l measured at
a wavelength of 304 nm; the sample was then stored in 80% meth-
anol/water until use. Two hundred milliliters liquid culture or one
plate (24 × 24 cm) yielded up to 40 mg of tetraene-containing sam-
ple. The methanol-extracted samples were brought to 20% metha-
nol with water and filtered to remove precipitated material. The
clear filtrate was slowly applied to an Omnifit column (250 × 25
mm, Supelco Catalog No. 56010) packed with SP-Sepharose,
Phast Flow (Pharmacia) equilibrated in the same solution. Under
these conditions, rimocidin (3a) and CE-108 (4a) eluted with the
unbound material, such as some pigment, whereas the amides CE-
108B (4b) and rimocidin B (3b) were completely retained. The col-
umn was exhaustively washed with the same solution. The polyene
amides were eluted from the column with 300 mM ammonium ace-
tate pH 5 in 20% methanol. The fractions containing the mixtures
of amides were desalted using Sep-Pak C18 (Waters) cartridges
and reconstituted in 20% methanol. The tetraene mixtures (15 mg)
were finally separated by HPLC using a semipreparative column
(Supelcosil PLC-8, 250.0 × 21.2 mm). The chromatographic param-
eters and the mobile phases, controlled with a Waters Automated
Gradient Controller, were: 12 min with 100% of B (ammonium ace-
tate 20 mM pH 5, ethanol 20%), 43 min of a binary gradient up to
50% of A (methanol) and 50% of B (curve 6); 35 min of a binary
gradient up to 100% of A (curve 8), and a constant flow of 5 ml/in. Fractions were collected at regular intervals (5 ml per fraction)
nd those carrying the purified isolated compounds were pooled
nd subjected to an additional desalting step, as above, and finally
reeze-dried twice. AB-400 was also purified from Streptomyces
p. RGU5.3 liquid cultures as above.
emolytic Activity Assays
he assays were carried out according to the method described by
ómez-Gómez et al. [18]. The polyene samples were weighed and
issolved in DMSO at 30 mg/ml. Increasing quantities of the dif-
erent polyenes were brought to a final volume of 100 l of DMSO
nd mixed by gently shaking with 500 l of PBS buffer [18] contain-
ng either 2.5% human or horse blood. After incubation at 37°C for
0 min without agitation, cells were pelleted by centrifugation, and
emolysis evaluated by measuring the absorbance at 545 nm. The
alues corresponding to total hemolysis were estimated with a sus-
ension of 2.5% horse blood in distilled water. Human blood
mostly erythrocytes) was provided by the Blood Bank of Ramón y
ajal Hospital (Madrid); horse blood was from Oxoid (defibrinated
lood). Amphotericin B and nystatin A used were from Sigma (cata-
og Nos. A-4888 and N-3503, respectively); pimaricin was from Cal-
iochem (527962). All were tested directly from the manufacturer
ources without further purification.
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